Table 1b. Features of included studies.
| References | Year | Patients (n) | Antibody | ERa status | Tumor Burden | |||
|---|---|---|---|---|---|---|---|---|
| ERα+ | ERα- | T1 % | N0 % | G3 % | ||||
| Borgquist et al.[11] | 2008 | 512 | ERβ1: anti-mouse ERβ1 monoclonal antibody (EMR02; Novocastra) | 407 | 72 | 63.1% | 63.1% | NA |
| 114# | 95 | 19 | NA | NA | NA | |||
| 139## | 114 | 25 | NA | NA | NA | |||
| Chantzi et al.[20] | 2013 | 95 | ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; Serotec) ERβ2/cx: anti-human ERβ2 monoclonal antibody (Clone # 57/3; Serotec) |
0 | 95 | 44.2% | 56.8% | 47.4% |
| Gruvberger-Saal et al.$, ¶¶¶¶[5] | 2007 | 425 | Pan-ERβ:anti-mouse ERβ monoclonal antibody (Clone 14C8; GeneTex) ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; Serotec) |
248 | 105 | 26.6% | 33.4% | NA |
| Guo et al. [2, 21]¶¶¶¶¶ | 2014 | 490 | Pan-ERβ: Unclear (Fuzhou Maixin Biotechnology Development) | NA | NA | 32.8% | 51.2% | 26.1% |
| Honma et al. §[2] | 2008 | 442 | Pan-ERβ:anti–rabbit polyclonal antibody (MYEB, M.Y) ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; DAKO) ERβ2/cx:anti-mouse ERβ2 monoclonal antibody (Clone # 57/3; Serotec) |
364 | 78 | 39.4% | 54.8% | NA |
| Hopp et al.[12] | 2004 | 305 | Pan-ERβ:anti-mouse ERβ monoclonal antibody (Clone 14C8; GeneTex) | 272 | 33 | 23.9% | 0.0% | 43.7% |
| 186 # | 176 | 10 | 26.9% | NA | 40.7% | |||
| 119## | 96 | 23 | 19.5% | NA | 48.3% | |||
| Kim et al.[13] | 2012 | 139 | NA | 139 | 0 | 61.4% | 42.4% | 20.7% |
| Mahle et al.§[14] | 2009 | 145 | Pan-ERβ:anti-mouse ERβ monoclonal antibody (Clone 14C8; GeneTex) | 97 | 48 | 37.0% | 51.7% | 24.3% |
| Mann et al.[1] | 2001 | 47## | Pan-ERβ:anti–rabbit polyclonal antibody (MYEB, M.Y) | 30 | 17 | NA | NA | NA |
| 118 # | 75 | 43 | NA | 100.0% | NA | |||
| Markey et al.[28] | 2009 | 121 | NA | 82 | 36 | 32.2% | 45.5% | 43.0% |
| Myers et al.[15] | 2004 | 150 | ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; Serotec) | 123 | 27 | NR | 37.3% | 49.3% |
| Nakopoulou et al.[3] | 2004 | 181 | ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; Serotec) | 117 | 61 | 27.1% | 38.1% | 29.3% |
| Novelli et al.[6] | 2008 | 936 | Pan-ERβ:anti-mouse ERβ monoclonal antibody (Clone 14C8; Abcam) ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; GeneTex) |
658 | 278 | 61.9% | 57.6% | 31.2% |
| Omoto et al.[18] | 2002 | 57 | Pan-ERβ: anti-rabbit ERβ polyclonal antibody βN; anti-chicken ERβ polyclonal antibody βT; ERβ1: anti-rabbit ERβ1 polyclonal antibody βC ERβ2/cx: anti-rabbit ERβcx polyclonal antibody |
39 | 18 | 21.1% | 62.5% | 14.0% |
| Omoto et al.[17] | 2001 | 88 | ERβ1: anti-rabbit ERβ1 polyclonal antibody βC | 62 | 26 | 22.7% | 52.3% | 4.5% |
| O'Neill et al.¶[16] | 2004 | 167 | ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; Serotec) | 83 | 44 | 40.6% | 53.3% | 45.5% |
| NA | 79 | 42 | ||||||
| Palmieri et al.[19] | 2004 | 82 | Pan-ERβ:a purified polyclonal antibody ERβ2/cx: anti-ERβcx sheep polyclonal antibody |
46 | 33 | 25.7% | 53.2% | 40.7% |
| Qui et al.[22] | 2009 | 308 | ERβ1:anti-rabbit ERβ polyclonal antibody(Ab-1, Oncogene research product) | 198 | 110 | 42.2% && | 37.8% | 39.6% |
| Shaaban et al.[23] | 2008 | 880 | ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; Serotec) ERβ2/cx: anti-human ERβ2 monoclonal antibody (Clone # 57/3; Serotec) |
451 | 219 | NA | NA | 45.8% |
| Sugiura et al.[24] | 2007 | 150 | ERβ1: anti-rabbit ERβ1 polyclonal antibody ERβ2/cx: anti-rabbit ERβ2/cx polyclonal antibody |
117 | 33 | 27.3% | 60.4% | 25.2% |
| NA | 117 | 33 | 27.3% | 60.4% | 25.2% | |||
| Vinayagam et al.¶,§[4] | 2007 | 141 | ERβ2/cx: anti-human ERβ2 monoclonal antibody (Clone # 57/3; Serotec) | 98 | 43 | 44.7% | 47.5% | 43.3% |
| 100 | NA | 70 | 30 | 44.0% | 49.0% | 42.0% | ||
| Wen et al.[25] | 2002 | 116 | Pan-ERβ: anti-goat ERβ polyclonal antibody(Santa Cruz) | 73 | 43 | 12.9% | 37.1% | 38.8% |
| Wimberly et al. [26] | 2014 | Yale-1:649 | ERβ1: anti-mouse ERβ1 monoclonal antibody (PPG5/10; Thermoscientific) ERβ5: anti-human ERβ5 monoclonal antibody (Clone 5/25; Serotec) |
246 | 208 | 28.0% | 42.6% | NA |
| Yale-2:398 | 158 | 102 | 54.8% | 51.4% | ||||
| Toronto: 976 | 288 | 118 | 65.3% | 100.0% | ||||
| NCI-PBCS: 1375 | 656 | 271 | 52.7% | 59.0% | ||||
| Yan et al.¶¶¶,§[27] | 2011 | 147 | Pan-ERβ:anti-mouse ERβ monoclonal antibody (Clone 14C8; Abcam) ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; Genetex) ERβ2/cx: anti-human ERβ2 monoclonal antibody (Clone # 57/3; Serotec) |
62 | 48 | 55.3% | 69.9% | 64.4% |
| Zhang et al.[29] | 2014 | 279 | ERβ1:anti-mouse ERβ1 monoclonal antibody (Clone PPG5/10; Serotec) ERβ2/cx: anti-human ERβ2 monoclonal antibody (Clone # 57/3; Serotec) |
131 | 21 | 70.5% | 41.6% | 24.8% |
#
Tamoxifen/endocrine-treated subgroup;
##
untreated subgroup; & Median;
$
Distant disease-free survival was considered to be disease-free survival in this study.
§
Breast cancer death and mortality were considered events affecting overall survival.
&&
size<3 cm was considered T1-stage.
¶
Postmenopausal patients.
¶¶
Estimated based on the description in the text.
¶¶¶
Familial breast cancer patients.
¶¶¶¶
Stage II patients.
¶¶¶¶¶
This group was reported in three publications involving the same study population. We selected the study with the longest follow-up period for analysis.
NA, Not available; ER, estrogen receptor;